Related Experiment Videos
Formoterol protects against platelet-activating factor-induced effects in asthma
J Gabrijelcic1, A Casas, R A Rabinovich
1Servei de Pneumologia i Al.lèrgia Respiratòria (ICPCT), Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
The European Respiratory Journal
|January 24, 2004
Summary
Long-acting beta2-agonists like formoterol may improve asthma symptoms by reducing airway inflammation and improving gas exchange. This study shows formoterol
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Respiratory Physiology
Background:
- Platelet-activating factor (PAF) causes airway inflammation, bronchoconstriction, and impaired gas exchange in asthma.
- The effects of long-acting beta2-agonists on PAF-induced asthma exacerbations require further investigation.
Purpose of the Study:
- To investigate the effects of inhaled formoterol on PAF-induced airway responses in asthma patients.
- To explore the anti-exudative properties of formoterol in the context of PAF challenge.
Main Methods:
- A double-blind, placebo-controlled, crossover study involving 12 asthma patients.
- Patients inhaled PAF (18 microg) 2 hours after receiving either formoterol (18 microg) or placebo.
- Measurements included respiratory resistance, arterial oxygenation, ventilation-perfusion (V'A/Q') inequality, and symptoms.
Main Results:
- Formoterol significantly reduced PAF-induced cough, dyspnea, respiratory resistance (67%), and arterial deoxygenation (50%).
- Ventilation-perfusion inequality, including pulmonary blood flow dispersion and heterogeneity, improved significantly (63% and 71%, respectively).
- PAF-induced facial flushing, neutropenia, and rebound neutrophilia were not affected by formoterol.
Conclusions:
- Inhaled formoterol at a clinical dose attenuates PAF-induced gas exchange abnormalities in asthma.
- These findings suggest formoterol may possess anti-exudative effects in the airways, beyond its bronchodilator properties.